Author

Chihyuan Chuang

Cytokinetics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Anand Bat-Erdene· 1 shared André deRosier· 1 shared Anne N. MurphyiD· 1 shared Bradley P. MorganiD· 1 shared Cassady E. RupertiD· 1 shared Darren Ting‐Cheung HweeiD· 1 shared Desirae Martin· 1 shared Fady I. MalikiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Anand Bat-Erdene

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEF

Saswata S. Sarkar, Meredith A. Redd, James J. Hartman, Darren Ting‐Cheung Hwee, Anand Bat-Erdene, Leo H. Kim, Chihyuan Chuang, Cassady E. Rupert, Najah Abi‐Gerges, Janette Rodriguez, Desirae Martin, André deRosier, Samantha Edell, Yangsong Wu, Lisette Yco, , Fady I. Malik

This paper describes ulacamten, a novel cardiac myosin inhibitor with distinct binding and inhibitory properties compared to existing CMIs, showing efficacy in improving cardiac function in a rodent model of HFpEF.

bioRxiv · Jan 26, 2026 · PreprintBiochemistry